K
Karen S. Raraigh
Researcher at Johns Hopkins University School of Medicine
Publications - 52
Citations - 1578
Karen S. Raraigh is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Cystic fibrosis & Medicine. The author has an hindex of 17, co-authored 35 publications receiving 1070 citations. Previous affiliations of Karen S. Raraigh include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
The future of cystic fibrosis care: a global perspective
Scott C. Bell,Marcus A. Mall,Hector H. Gutierrez,Milan Macek,Susan Madge,Jane C. Davies,Pierre-Régis Burgel,Elizabeth Tullis,Claudio Castaños,Carlo Castellani,Catherine A. Byrnes,Fiona Cathcart,Sanjay H. Chotirmall,Rebecca Cosgriff,Irmgard Eichler,Isabelle Fajac,Christopher H. Goss,Pavel Drevinek,Philip M. Farrell,Anna M. Gravelle,Trudy Havermans,Nicole Mayer-Hamblett,Nataliya Kashirskaya,Eitan Kerem,Joseph L. Mathew,Edward F. McKone,Lutz Naehrlich,Samya Z. Nasr,Gabriela R. Oates,Ciaran O'Neill,Ulrike Pypops,Karen S. Raraigh,Steven M. Rowe,Kevin W Southern,Sheila Sivam,Anne L. Stephenson,Anne L. Stephenson,Marco Zampoli,Felix Ratjen +38 more
TL;DR: Advances in clinical care have been multifaceted and include earlier diagnosis through the implementation of newborn screening programmes, formalised airway clearance therapy, and reduced malnutrition through the use of effective pancreatic enzyme replacement and a high-energy, high-protein diet.
Journal ArticleDOI
Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis
Harriet Corvol,Harriet Corvol,Scott M. Blackman,Pierre-Yves Boëlle,Paul J. Gallins,Rhonda G. Pace,Jaclyn R. Stonebraker,Frank J. Accurso,Frank J. Accurso,Annick Clement,Annick Clement,Joseph M. Collaco,Hong Dang,Anthony T. Dang,Arianna Franca,Jiafen Gong,Loïc Guillot,Katherine Keenan,Weili Li,Fan Lin,Michael V. Patrone,Karen S. Raraigh,Lei Sun,Yi-Hui Zhou,Wanda K. O'Neal,Marci K. Sontag,Marci K. Sontag,Hara Levy,Peter R. Durie,Johanna M. Rommens,Mitchell L. Drumm,Fred A. Wright,Lisa J. Strug,Garry R. Cutting,Michael R. Knowles +34 more
TL;DR: This paper used genome-wide association analysis to identify genetic modifiers of CF lung disease, the primary cause of mortality, and provided new insights into potential targets for modulating lung disease severity in CF.
Journal ArticleDOI
Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators
Sangwoo T. Han,Andras Rab,Matthew J. Pellicore,Emily Davis,Allison F. McCague,Taylor A. Evans,Anya T. Joynt,Zhongzhou Lu,Zhiwei Cai,Karen S. Raraigh,Jeong S. Hong,David N. Sheppard,Eric J. Sorscher,Garry R. Cutting +13 more
TL;DR: Results indicate that most individuals with CF carrying missense variants are likely to respond modestly to currently available modulator therapy, while a small fraction will have pronounced responses, and likely to derive the greatest benefit from combination therapy.
Journal ArticleDOI
Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice Sites
Melissa Lee,Patrick Roos,Neeraj Sharma,Melis Atalar,Taylor A. Evans,Matthew J. Pellicore,Emily Davis,Anh Thu N. Lam,Susan E. Stanley,Sara E. Khalil,George M. Solomon,Doug Walker,Karen S. Raraigh,Briana Vecchio-Pagan,Mary Armanios,Garry R. Cutting +15 more
TL;DR: The findings suggest that cryptic splice-site activation is more common than previously thought and should be routinely considered for all variants within the transcribed regions of genes.
Journal ArticleDOI
Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.
Allison F. McCague,Karen S. Raraigh,Matthew J. Pellicore,Emily F. Davis-Marcisak,Taylor A. Evans,Sangwoo T. Han,Zhongzhou Lu,Anya T. Joynt,Neeraj Sharma,Carlo Castellani,Joseph M. Collaco,Mary Corey,Michelle Huckaby Lewis,Chris M. Penland,Johanna M. Rommens,Anne L. Stephenson,Patrick R. Sosnay,Garry R. Cutting +17 more
TL;DR: This study provides reference standards for clinical outcomes that may be achieved by increasing CFTR function and Therapeutic responses to modulators corresponded closely to predictions from the CFTR2‐derived relationship between CFTR genotype function and phenotype.